Results 181 to 190 of about 227,102 (266)

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer. [PDF]

Onco Targets Ther
Zhang HB, Yan Y, Pang JP, Kong MT, Zhu QK.   +4 more
europepmc   +1 more source

Targeting Microbiome Metabolites: Reshaping Immunotherapy and Clinical Management Strategies for Colorectal Cancer

iMetaMed, EarlyView.
The occurrence and progression of colorectal cancer are intricately linked to metabolites produced by the gut microbiota. Metabolites generated by pathogenic microbial communities can promote colorectal cancer development by reshaping the immune microenvironment.
Xinrui Yang, Ke Zhang, Lijie Xia, Jinyao Li   +3 more
wiley   +1 more source

Engineering Immortalized Bovine Granulosa Cells Using a Triple-Gene Approach: Mutant CDK4, Cyclin D1, and TERT. [PDF]

Cell Biol Int
Bai L, Takahashi M, Kobayashi J, Eitsuka T, Matsusaka H, Ozaki T, Sugano E, Tomita H, Xu Y, Kawamura K, Nakagawa K, Kiyono T, Fukuda T.   +12 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Correction: Liu et al. Functional Analysis of the Cyclin E Gene in the Reproductive Development of Rainbow Trout (<i>Oncorhynchus mykiss</i>). <i>Biology</i> 2025, <i>14</i>, 862. [PDF]

Biology (Basel)
Liu E, Song H, Gu W, Wang G, Fan P, Ge K, Sun Y, Li D, Xu G, Huang T.   +9 more
europepmc   +1 more source

Holistic bone developing microenvironment engineered apoptotic extracellular vesicles recapitulate multidimensional developmental signatures in adult and senile bone repair

Interdisciplinary Medicine, EarlyView.
The developing bone was identified as an M2a‐like macrophage driven immune microenvironment with multidimensional developmental signatures. hME‐ApoEVs were successfully fabricated via stimulating the M2a‐like developing microenvironment in vitro and confirmed its recapitulation of developmental features.
Xiaoran Yu, Jieyun Xu, Yuan Zhao, Xinyu Guo, Hongcheng Chen, Junlong Xue, Yong Ao, Linjun Zhang, Xiaomeng Gao, Xueli Mao, Songtao Shi, Zetao Chen   +11 more
wiley   +1 more source

Correction: Anaphase onset requires CKS-1-mediated destruction of securin in meiosis I and cyclin B1 in meiosis II. [PDF]

J Cell Biol
Yang J, Sumiyoshi E, Bowerman B.
europepmc   +1 more source

Engineered extracellular vesicles for precision renal therapy: Bioengineering strategies and clinical translation

Interdisciplinary Medicine, EarlyView.
Engineered extracellular vesicles (EVs) offer a versatile platform for kidney‐targeted therapy. This review summarizes bioengineering strategies, including cargo loading, surface modification, biomimetic fabrication, and biomaterial integration. We highlight translational challenges and propose future solutions to accelerate the clinical application of
Linru Shi, Bei Li, Wanzhu Liu, Haifeng Wu, Wenrong Xu, Cheng Ji, Hui Qian   +6 more
wiley   +1 more source

Decyl caffeate inhibits the proliferation of human triple negative breast cancer cells. [PDF]

Biomedicine (Taipei)
Chao CY, Shyu WC, Lin CL, Chiang EI, Kuo YH, Tang FY.   +5 more
europepmc   +1 more source